Document is current
Any future updates will be listed below
-
Authors
Gao, Yu
Cai, Curtis https://orcid.org/0000-0002-3490-4361
Grifoni, Alba https://orcid.org/0000-0002-2209-5966
Müller, Thomas R. https://orcid.org/0000-0001-5331-5522
Niessl, Julia https://orcid.org/0000-0001-8852-1924
Olofsson, Anna
Humbert, Marion https://orcid.org/0000-0002-1710-1479
Hansson, Lotta
Österborg, Anders
Bergman, Peter
Chen, Puran
Olsson, Annika
Sandberg, Johan K. https://orcid.org/0000-0002-6275-0750
Weiskopf, Daniela
Price, David A. https://orcid.org/0000-0001-9416-2737
Ljunggren, Hans-Gustaf
Karlsson, Annika C. https://orcid.org/0000-0002-2028-8393
Sette, Alessandro https://orcid.org/0000-0001-7013-2250
Aleman, Soo
Buggert, Marcus https://orcid.org/0000-0003-0633-1719
- License Information
-
More Information
Article History
Received: 30 December 2021
Accepted: 14 January 2022
First Online: 14 January 2022
Competing interests
: A.S. is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress and Repertoire, and the La Jolla Institute has filed patents to protect various aspects of the T cell epitope and vaccine design work. S.A. has received honoraria from Gilead, AbbVie, MSD and Biogen and research grants from Gilead and AbbVie. M.B. is a consultant for Oxford Immunotec. The other authors declare no conflicts of interest.
